<DOC>
	<DOCNO>NCT00626808</DOCNO>
	<brief_summary>This retrospective cohort study child include large medical insurance claim database .</brief_summary>
	<brief_title>A Post Marketing Evaluation Effectiveness FluMist Risk Minimization Plan Children</brief_title>
	<detailed_description>- To evaluate rate FluMist administration compare influenza vaccine use follow pediatric population : - Children young 24 month age - Children 24-59 month age claim associate diagnosis asthma - Children 24-59 month age without claim associate diagnosis asthma , dispense medication wheeze - Children 24-59 month age immunosuppression - To describe , child population receive FluMist , type number Emergency Room visit hospitalization associate insurance claim within 42 day receive FluMist - To explore rationale FluMist immunization pediatric population exclude recommended usage characterizing use population</detailed_description>
	<mesh_term>Respiratory Sounds</mesh_term>
	<criteria>Children le 24 month age August January/February . Children &lt; 24 59 month age August January/February , : two outpatient claim asthma , one inpatient/emergency room claim asthma , one outpatient claim asthma least one SABA prescription define 12month period . Children &lt; 24 59 month age August January/February , without claim associate diagnosis asthma , least one dispense SABA , indicate pharmacy claim define 12month period . Children 24 59 month age August January/February evidence immunosuppression prior date influenza vaccination base available medical pharmacy claim .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>